文献速递多重用药老年慢病共病管理

美国长期护理机构2型糖尿病降糖药处方与低血糖观察性研究

Medication Prescribing for Type 2 Diabetes in the US Long-Term Care Setting: Observational Study.
PubMed 文献 · J Am Med Dir Assoc · 2023-04-21

该研究利用美国长期护理机构电子健康记录数据库,对2016至2020年每年71,200至120,861名≥65岁、住院≥100天的2型糖尿病居民进行系列横断面分析。68%至73%的居民被处方至少1种降糖药,处方模式五年间相对稳定。每年35%的居民发生1级低血糖,24%至25%发生2级低血糖。

要点

  • 68%至73%的长期护理2型糖尿病居民每年被处方至少1种降糖药,2016至2020年处方模式相对稳定。
  • 每年35%的居民发生1级低血糖(血糖≥54至<70 mg/dL),仅用口服药者为10%至12%,用注射药者≥44%。
  • 每年24%至25%的居民发生2级低血糖(血糖<54 mg/dL),研究提示糖尿病管理存在改进空间。

核心结论

  • 研究结果提示,美国长期护理机构2型糖尿病居民的糖尿病管理存在改进机会。

研究设计与样本

  • 系列横断面研究,使用去标识化的真实世界电子健康记录数据库,覆盖美国长期护理机构。
  • 纳入≥65岁、2型糖尿病、在2016至2020年任一研究年度于长期护理机构记录住院≥100天者,排除接受姑息或临终关怀者。
  • 每年纳入71,200至120,861名长期护理2型糖尿病居民。
  • 降糖药处方按给药途径(口服或注射)和药物类别汇总为曾处方,并按年龄亚组、<3 vs ≥3种共病及肥胖状态分层。
  • 计算每年曾处方降糖药者中发生≥1次低血糖事件的年度百分比。

主要发现

  • 2016至2020年各年度68%至73%的居民被处方至少1种降糖药,其中口服药为59%至62%,注射药为70%至71%。
  • 最常处方的口服药为二甲双胍,其次为磺脲类和二肽基肽酶4抑制剂;最常处方的注射方案为基础加餐时胰岛素。
  • 2016至2020年处方模式总体及按患者亚组均保持相对一致。
  • 每个研究年度35%的长期护理2型糖尿病居民发生1级低血糖(血糖≥54至<70 mg/dL),其中仅用口服药者为10%至12%,用注射药者≥44%。
  • 总体24%至25%的居民发生2级低血糖(血糖<54 mg/dL)。

关键数值与推荐

  • 1级低血糖定义为血糖≥54至<70 mg/dL;2级低血糖定义为血糖<54 mg/dL。
  • 纳入标准为≥65岁、2型糖尿病、长期护理机构记录住院≥100天;排除接受姑息或临终关怀者。
  • 降糖药处方统计为曾处方,即同一药物多次处方只计一次。

临床怎么用

  • 原文未报告临床实践推荐。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To characterize prescribing of glucose-lowering medication annually and to quantify the annual frequency of hypoglycemia among residents in long-term care (LTC) facilities with type 2 diabetes mellitus (T2DM). DESIGN: Serial cross-sectional study using a deidentified real-world database comprising electronic health records from LTC facilities. SETTING AND PARTICIPANTS: Individuals eligible for this study were ≥65 years old with T2DM and recorded stay of ≥100 days at an LTC facility in the United States in any of 5 study years (2016-2020), excluding individuals receiving palliative or hospice care. METHODS: Drug orders (prescriptions) for glucose-lowering medications for each LTC resident with T2DM in each calendar year were summarized by administration route (oral or injectable) and by drug class as ever-prescribed (ie, multiple prescriptions were included once), overall and stratified by age subgroup, <3 vs ≥3 comorbidities, and obesity status. We calculated the annual percentage of patients ever prescribed glucose-lowering medication each year, overall and by medication category, who experienced ≥1 hypoglycemic events. RESULTS: Among 71,200 to 120,861 LTC residents with T2DM included each year from 2016 to 2020, 68% to 73% (depending on the year) were prescribed ≥1 glucose-lowering medications, among them oral agents for 59% to 62% and injectable agents for 70% to 71%. Metformin was the most commonly prescribed oral agent, followed by sulfonylureas and dipeptidyl peptidase 4 inhibitors; basal plus prandial insulin was the most commonly prescribed injectable regimen. Prescribing patterns remained relatively consistent from 2016 to 2020, both overall and by patient subgroup. During each study year, 35% of LTC residents with T2DM experienced level 1 hypoglycemia (glucose ≥54 to <70 mg/dL), including 10% to 12% of those prescribed only oral agents and ≥44% of those prescribed injectable agents. Overall, 24% to 25% experienced level 2 hypoglycemia (glucose concentration <54 mg/dL). CONCLUSIONS AND IMPLICATIONS: Study findings suggest that opportunities exist for improving diabetes management for LTC residents with T2DM.

来源:J Am Med Dir Assoc,查看原文。版权归原作者所有。

引用

  1. Pandya N, Jung M, Norfolk A, et al. Medication Prescribing for Type 2 Diabetes in the US Long-Term Care Setting: Observational Study. J Am Med Dir Assoc. 2023. PMID: 37094748. doi:10.1016/j.jamda.2023.03.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。